Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2026 According to a Solid Biosciences media release, company announced that the first participant has been dosed in IMPACT DUCHENNE trial.
20 Mar 2026 According to a Solid Biosciences media release, additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003.
20 Mar 2026 According to a Solid Biosciences media release, participant screening is underway and the Company anticipates dosing the first participant in the IMPACT DUCHENNE trial in April 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com